Literature DB >> 3309973

Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.

J M Brisset1, L Boccon-Gibod, H Botto, M Camey, G Cariou, J M Duclos, F Duval, D Gontiès, R Jorest, L Lamy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3309973

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  5 in total

Review 1.  Review of assessment of total androgen blockade as treatment of metastatic prostate cancer.

Authors:  J Geller
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

Review 2.  Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  M G Harris; S G Coleman; D Faulds; P Chrisp
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

3.  Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.

Authors:  C D Schiller; M R Schneider; H Hartmann; A H Graf; H Klocker; G Bartsch
Journal:  Urol Res       Date:  1991

4.  Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate.

Authors:  L Pendyala; P J Creaven; R Huben; D Tremblay; C Bertagna
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.

Authors:  H Lukka; T Waldron; L Klotz; E Winquist; J Trachtenberg
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.